A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach.
Alterations in cellular phosphorylation patterns have been implicated in a number of diseases, including cancer, through multiple mechanisms. Herein we present a survey of the phosphorylation profiles of an isogenic pair of human cancer cell lines with opposite metastatic phenotype. Phosphopeptides were enriched from tumor cell lysates with titanium dioxide and zirconium dioxide, and identified with nano-LC-MS/MS using an automatic cross-validation of MS/MS and MS/MS/MS (MS2+MS3) data-dependent neutral loss method. A spectral counting quantitative strategy was applied to the two cell line samples on the MS2-only scan, which was implemented successively after each MS2+MS3 scan in the same sample. For all regulated phosphopeptides reported by spectral counting analysis, sequence and phosphorylation site assignments were validated by a MS2+MS3 data-dependent neutral loss method. With this approach, we identified over 70 phosphorylated sites on 27 phosphoproteins as being differentially expressed with respect to tumor cell phenotype. The altered expression levels of proteins identified by LC-MS/MS were validated using Western blotting. Using network pathway analysis, we observed that the majority of the differentially expressed proteins were highly interconnected and belong to two major intracellular signaling pathways. Our findings suggest that the phosphorylation of isoform A of lamin A/C and GTPase activating protein binding protein 1 is associated with metastatic propensity. The study demonstrates a quantitative and comparative proteomics strategy to identify differential phosphorylation patterns in complex biological samples.
Xie
Xiaolei
X
Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109-0656, USA.
Feng
Shun
S
Vuong
Huy
H
Liu
Yashu
Y
Goodison
Steve
S
Lubman
David M
DM
D015153:Blotting, Western; D001943:Breast Neoplasms / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D006801:Humans; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000378:metabolism; D010446:Peptide Fragments / Q000032:analysis / Q000378:metabolism; D010641:Phenotype; D010750:Phosphoproteins / Q000032:analysis* / Q000378:metabolism; D010766:Phosphorylation; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results; D015398:Signal Transduction; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014025:Titanium / Q000737:chemistry; D015040:Zirconium / Q000737:chemistry
D009363:Neoplasm Proteins; D010446:Peptide Fragments; D010750:Phosphoproteins; C009495:titanium dioxide; D015040:Zirconium; D014025:Titanium; C028541:zirconium oxide
J Proteome Res. 2006 Sep;5(9):2339-47
16944946
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1311-5
6246487
Cell. 2007 Dec 14;131(6):1190-203
18083107
Biochim Biophys Acta. 2008 Feb;1784(2):276-84
18082151
Clin Cancer Res. 2002 Jan;8(1):61-74
11801541
Anal Chem. 2007 Feb 15;79(4):1301-10
17297928
Exp Mol Pathol. 2007 Feb;82(1):85-90
17046747
J Proteome Res. 2008 Nov;7(11):4727-35
18808171
J Proteome Res. 2008 Apr;7(4):1640-9
18314942
Cell. 2006 Nov 3;127(3):635-48
17081983
Anal Chem. 2004 Jul 15;76(14):4193-201
15253663
J Cell Mol Med. 2008 Jan-Feb;12(1):209-18
18053086
J Med Genet. 2005 Mar;42(3):214-20
15744034
Am J Pathol. 2005 May;166(5):1565-79
15855655
Mol Cell Proteomics. 2005 Sep;4(9):1265-72
15958392
J Proteome Res. 2008 Jan;7(1):51-61
18173218
Cancer Res. 2005 Jul 15;65(14):6042-53
16024604
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18928-33
17138671
Mol Cell Proteomics. 2008 Jan;7(1):71-87
17872894
Mol Cell Biol. 2001 Nov;21(22):7747-60
11604510
Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98
18925859
J Proteome Res. 2007 Nov;6(11):4150-62
17924679
Mol Cell Proteomics. 2006 Oct;5(10):1799-810
16844681
Cell Mol Life Sci. 2004 Jun;61(12):1475-84
15197471
Eur J Cell Biol. 1993 Dec;62(2):237-47
7925482
Proteomics. 2004 Sep;4(9):2754-65
15352249
Breast Cancer Res. 2007;9(4):211
17705881
Mol Cell Proteomics. 2005 Oct;4(10):1487-502
15979981
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3808-14
14506175
Mol Cell Proteomics. 2009 Jun;8(6):1436-49
19321434
Cancer Res. 2002 Mar 1;62(5):1251-5
11888885
J Proteome Res. 2009 Mar;8(3):1168-82
19178300